The World Health Organization (WHO) today approved the first mpox vaccine for use in adults — and also said it can be used for babies, children, teens and pregnant women if they are in “outbreak settings where the benefits of vaccination outweigh the potential risks.”
WHO’s approval of Bavarian Nordic’s vaccine will help governments and international agencies such as the Gavi, the Vaccine Alliance, and UNICEF, buy it, MedicalXpress reported.
The MVA-BN vaccine — short for “Modified Vaccinia Ankara-Bavarian Nordic” — is a smallpox/mpox vaccine. It is sold in the U.S. under the name Jynneos.
WHO Assistant Director-General Yukiko Nakatani said, “The decision can also help national regulatory authorities to fast-track approvals, ultimately increasing access to quality-assured mpox vaccine products.”
Children’s Health Defense (CHD) Chief Scientific Officer Brian Hooker called the WHO’s approval of the shot for infants and children in Africa “a train wreck in the making.”